🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

🧬 New study highlights germline risks in gastric cancer (GC): 📊 Of 3,706 GC patients tested, 13.3% had pathogenic/likely pathogenic variants (PGVs) 🧠 Most common genes: 🔹 BRCA1/2, PALB2, ATM (HRR) – 35% 🔹 CDH1, CTNNA1 (Hereditary Diffuse GC) – 19.5% 🔹 Lynch syndrome genes –

Evolving Therapeutics for Resectable Esophageal Adenocarcinoma Great Review👇 jnccn.org/view/journals/…

June Issue: Operative Strategies for Beyond Total #MesorectalExcision Surgery for #RectalCancer rdcu.be/eqUec Anthony Villano, MD Syed A. Ahmad

⁦ESMO - Eur. Oncology⁩ recommendations on BC germline testing: 7 genes should be included in a panel: BRCA1, BRCA2, PALB2, RAD51C, RAD51D, BRIP1, and TP53 (≤ age 40) ATM and CHEK2 excluded due to limited impact on mortality ⁦⁦ ⁩ ⁦⁦OncoAlert⁩ annalsofoncology.org/article/S0923-…

Perioperative durvalumab + FLOT; ✅EFS benefit vs chemo alone in resectable gastric/GEJ cancers (HR=0.71; p<0.001). ✅2-year EFS: 67.4% vs 58.5% ✅OS trend (HR=0.78) ⁦⁦NatureRevClinOncol⁩ ⁦OncoTwit⁩ ⁦OncoAlert⁩ ⁦Gastric Cancer Foundation⁩ nature.com/articles/s4157…

The Milan Consensus recommendations for peripheral CCA are available. International experts delivered statements that were evaluated by an independent jury. It exposes and grades the available evidence and the research needs pubmed.ncbi.nlm.nih.gov/40478744/ Hospital Clínic IDIBAPS

🚨 Just out in NEJM: #KEYNOTE689 💉🧠 Periop #pembrolizumab (neoadj + adj) + surgery + RT/CRT improves EFS in resectable LA-#HNSCC. First +ve phase 3 in this space! 🔥 🔹 EFS @ 3 yrs CPS ≥10: 59.8% vs 45.9% CPS ≥1: 58.2% vs 44.9% All pts: 57.6% vs 46.4% 📉 HR ~0.66–0.73 🧪 MPR:

My own protocol against CDDP-induced AKI during #HIPEC for #OvaCa 👇 🔗dovepress.com/neoadjuvant-ch… Peritoneal Surface Oncology Group International Donal Brennan Sociedade Brasileira de Cirurgia Oncológica (SBCO) Annals of Surgical Oncology European Society of Surgical Oncology (ESSO) Kurt Van der Speeten Wim Ceelen INDEPSO Oliver Zivanovic Team Ovary, Memorial Sloan Kettering Cancer Center Anna Fagotti ESGO

St. Gallen/Vienna 2025 Summary of Key Messages on Therapy in Early Breast Cancer from the 2025 St. Gallen International Breast Cancer Conference karger.com/brc/article/do…

📙Management of peritoneal mesothelioma Consensus guideline ACS Journal Cancer 👉acsjournals.onlinelibrary.wiley.com/doi/10.1002/cn… #cancer #oncology #MedX OncoAlert

HER2 IHC 3+ testing in 65,000+ solid tumors shows a 3.1% positivity rate Most common➡️Bladder (13.9%), uterine serous (13.6%), GEJ (12.1%). Least common➡️Glioma, sarcoma, SCLC(0%) 📌Bx and resection samples yield largely similar HER2 positivity rates jamanetwork.com/journals/jamao…

Adjuvant ET in EBC = Individualised Approach Nice article from ESMO

List of adjuvant imatinib trials in resected GIST ASCO Dr Sameer Rastogi

ESMO GI 2025 | #MATTERHORN Update. Perioperative Durvalumab + FLOT 🆚 Placebo + FLOT in resectable G/GEJ adenocarcinoma 🎯 Primary endpoint met 🔹 EFS HR 0.71 (95% CI: 0.58–0.86, p<0.001) 🔹 mEFS: NR vs 32.8 mo 🔹 OS HR: 0.78 (p=0.025, NS at interim) 🔹 QoL ✅ (no

Fresh out of the oven! Great read: HIPEC for Colorectal peritoneal Mets Annals of Surgical Oncology link.springer.com/article/10.124… UChicago Surgery UChicago Medicine UChicago Pritzker School of Medicine Jason M Foster Garrett Nash

🚨 Who should undergo pancreatic cancer screening? 🤔 #ESMOGI25 ▪️PRSS1 (Hereditary Pancreatitis): RR ~53–87, risk up to 55% ▪️STK11 (Peutz-Jeghers): RR ~132, lifetime risk 11–36% ▪️CDKN2A (FAMMM): RR ~20–40, risk up to 25% ▪️SPINK1, TP53, BRCA1/2, PALB2, ATM, Lynch, FPC: All

Recurrence Patterns of Esophageal Adenocarcinoma in the Phase III ESOPEC Trial Comparing FLOT With CROSS 💥FLOT enhances survival through superior systemic control, with locoregional control similar to CROSS ascopubs.org/doi/10.1200/JC…

N1 axillary disease post neoadjuvant chemo in Early Stage Breast Cancer? If clinically N0, SLNB with >= 3 nodes or TAD is fine. Residual ITCs: ALND can be avoided. Residual micromets: ALND could be avoided, still standard for TNBC. Residual macromets: ALND still standard.

Early-Onset Gastrointestinal Cancers. JAMA 2025 ⚠️Colorectal 54%, gastric 24%, esophageal 13% & pancreatic 8.6%. 🌎 Incidence rising worldwide. - Risks: obesity, diet, EtOH - Germline muts in ~30% - Survival improvement needed. OncoAlert jamanetwork.com/journals/jama/…

The upcoming IASG-NCG Virtual Tumor Board session will be held this Friday, the 25th, with a focus on GISTs. A diverse set of interesting cases has been curated for discussion.Look forward to your participation. iecho.org/public/program…